L-Carnitine 500
L-Carnitine 500 Dragon Pharma β Overview
L-Carnitine 500 Dragon Pharma delivers 500 mg of pharmaceutical-grade L-carnitine per milliliter in an injectable solution β a format that bypasses the poor and highly variable oral bioavailability that limits supplement-grade carnitine tablets and capsules. Oral L-carnitine reaches systemic circulation at roughly 14β18% of the ingested dose under optimal conditions; injectable L-carnitine achieves near-100% bioavailability with predictable plasma kinetics and measurable tissue delivery. This difference is pharmacologically meaningful: clinical studies demonstrating carnitine's effects on muscle carnitine content, fat oxidation, and exercise metabolism have predominantly used intravenous or intramuscular delivery because oral supplementation does not reliably raise muscle carnitine concentrations at practical doses.
L-Carnitine is a conditionally essential quaternary ammonium compound synthesized endogenously from lysine and methionine. Its primary physiological role is the obligatory transport of long-chain fatty acids (LCFA) across the inner mitochondrial membrane β a step that is rate-limiting for beta-oxidation and, therefore, for fat utilization as a fuel source. Without adequate intramitochondrial carnitine, LCFA accumulate in the cytoplasm as acylcarnitine esters and cannot enter the beta-oxidation pathway regardless of the lipolytic signal driving their mobilization. By raising muscle carnitine concentrations above the endogenous baseline, the injectable Dragon Pharma format available at Steroid Warehouse ensures this transport step does not become the bottleneck limiting fat oxidation during training.
About the Compound: L-Carnitine
L-Carnitine (L-3-hydroxy-4-(trimethylammonio)butanoate) is a small zwitterionic molecule produced endogenously in the liver and kidneys from the amino acids L-lysine and L-methionine, with ascorbate, niacin, pyridoxine, and iron as required cofactors. Approximately 98% of the body's total carnitine pool resides in skeletal muscle, where it functions primarily as an acyl group acceptor and donor within the carnitine palmitoyltransferase (CPT) enzyme system. CPT-1, located on the outer mitochondrial membrane, transfers the acyl group from long-chain fatty acyl-CoA to carnitine, forming acylcarnitine; this acylcarnitine is then transported by carnitine-acylcarnitine translocase (CACT) across the inner membrane; inside the mitochondrial matrix, CPT-2 regenerates acyl-CoA for entry into the beta-oxidation spiral. Free carnitine released by CPT-2 is returned to the cytoplasm by CACT, completing the transport cycle.
The practical consequence of this biochemistry is that carnitine availability within the mitochondrial inner membrane space is a prerequisite for fat utilization as a fuel β not just a modulator of rate. At high exercise intensity, when pyruvate flux increases and acetyl-CoA production from glucose exceeds the TCA cycle's capacity to process it, carnitine also acts as an acetyl group buffer: carnitine acetyltransferase (CrAT) converts the surplus acetyl-CoA to acetylcarnitine, regenerating free CoA and keeping the CoA pool available for continued metabolic flux. This dual role β LCFA transport at lower intensities and CoA buffering at high intensities β means carnitine availability affects exercise metabolism across the full intensity spectrum. Injectable delivery at 500 mg/mL allows precise, bioavailable dosing that oral supplementation cannot match.
What L-Carnitine Does
Injectable L-carnitine raises muscle carnitine content above the endogenous baseline, enabling more efficient fatty acid utilization across a range of training and metabolic contexts.
- LCFA transport into mitochondria β rate-limiting step for fat oxidation β at rest and low-to-moderate exercise intensity, the primary substrate for ATP production in skeletal muscle is long-chain fatty acids; entry into the beta-oxidation spiral requires CPT-1-mediated acylcarnitine formation; when free carnitine is available in excess, this step is not rate-limiting and LCFA oxidation proceeds at its enzymatic maximum; injectable L-carnitine ensures the intramitochondrial carnitine pool is fully saturated rather than operating at the lower end of endogenous supply
- Glycogen sparing during moderate-intensity exercise β by increasing fat as a fuel source at submaximal intensities, higher muscle carnitine content reduces the rate of glycogen breakdown; research with insulin co-administration to maximize muscle carnitine loading demonstrated a ~25% reduction in muscle glycogen use during a standardized exercise protocol; for athletes training in a glycogen-limited state (fasted training, caloric deficit), this shift toward fat oxidation improves training sustainability and preserves glycogen for high-intensity effort
- CoA buffer at high exercise intensity β metabolic flexibility β during anaerobic or high-intensity glycolytic exercise, pyruvate dehydrogenase generates acetyl-CoA faster than the TCA cycle can oxidize it; the resulting acetyl-CoA accumulation inhibits its own production via product feedback; carnitine acetyltransferase (CrAT) exports surplus acetyl-CoA as acetylcarnitine, regenerating free CoA and sustaining PDH flux; higher muscle carnitine content increases CrAT buffering capacity, delaying the metabolic brake that limits sustained high-intensity effort
- Recovery support and androgen receptor upregulation β several controlled studies have reported post-exercise reductions in markers of muscle damage (myoglobin, creatine kinase) and markers of hypoxic stress (malondialdehyde) with L-carnitine supplementation; separate research has documented that L-carnitine increases androgen receptor density in skeletal muscle, a finding relevant to athletes simultaneously running testosterone-based AAS protocols β higher receptor density may amplify the tissue response to the same circulating androgen concentration
- Insulin sensitivity and glucose disposal support β carnitine plays a role in mitochondrial acylcarnitine export, preventing intramitochondrial acyl-CoA accumulation that is associated with reduced insulin signaling; studies using intravenous carnitine have shown improvements in whole-body glucose disposal rates; at high doses delivered parenterally, L-carnitine may modestly improve peripheral insulin sensitivity, a secondary benefit in athletes managing carbohydrate-heavy training diets or post-cycle insulin resistance
Who It's For
Injectable L-Carnitine 500 Dragon Pharma is for athletes who want the pharmacokinetic reliability of parenteral carnitine delivery β where plasma levels and tissue uptake are predictable β rather than the variable and poor absorption of oral carnitine. It is not a stimulant-based fat burner and does not produce the acute thermogenic or adrenergic effects of compounds like Helios; it functions by ensuring the enzymatic machinery for fat oxidation has the substrate it requires to operate at capacity.
What sets injectable L-carnitine apart: oral carnitine supplementation has been consistently shown in clinical studies to fail at meaningfully raising muscle carnitine content within practical supplementation windows (weeks to months at normal oral doses), because the rate-limiting step for carnitine muscle loading is not dietary intake but insulin-dependent transport into muscle cells. Injectable administration bypasses gut absorption variability entirely and delivers carnitine to the systemic circulation at near-100% efficiency; the subsequent muscle loading then depends on insulin signaling, which is why some protocols combine injectable carnitine with post-workout insulin-stimulating nutrition.
Ideal use cases:
- Athletes in a caloric deficit cutting phase where fat oxidation efficiency is the primary goal β injectable L-carnitine at 1,000β2,000 mg pre-workout ensures the LCFA-to-mitochondria transport step is not rate-limiting during the training session, maximizing fat as a fuel source during fasted or semi-fasted training
- Athletes on testosterone-based AAS cycles who want to potentiate androgen receptor response β L-carnitine's documented effect on androgen receptor upregulation in skeletal muscle makes it a logical addition to a testosterone stack for users who want to maximize the anabolic signal from their circulating testosterone level
- Athletes with high training volume where recovery between sessions is a limiting factor β L-carnitine's reduction in post-exercise muscle damage markers supports faster recovery and higher training frequency without additional pharmacological intervention
Who should consider an alternative approach: athletes who want acute thermogenic fat loss with a strong adrenergic component β rapid heart rate elevation, thermogenesis, and direct beta-adrenergic lipolysis β are better served by Helios Dragon Pharma. L-Carnitine does not stimulate lipolysis directly; it facilitates the downstream utilization of fatty acids that lipolysis releases. The two mechanisms are complementary, not interchangeable.
L-Carnitine vs Alternatives
| Compound | Key Differences | Choose L-Carnitine When | Choose Alternative When |
|---|---|---|---|
| Helios Dragon Pharma Injectable clenbuterol + yohimbine Β· adrenergic lipolysis |
Helios combines clenbuterol (beta-2 adrenergic agonist) with yohimbine (alpha-2 antagonist) to directly stimulate lipolysis β the release of free fatty acids from adipocytes; Helios acts upstream of carnitine in the fat-burning cascade by mobilizing FFA from fat stores, while carnitine acts downstream by transporting the mobilized FFA into the mitochondria; Helios produces acute thermogenesis, stimulant effects (elevated HR, tremor, sweating), and localized subcutaneous fat reduction at the injection site; carnitine has no stimulant properties and no direct lipolytic effect | Fat oxidation efficiency during training is the goal without stimulant effects; AAS stack with androgen receptor upregulation is the objective; recovery support is needed; no tolerance to adrenergic stimulation; caloric deficit with high training volume is the context | Acute thermogenesis and direct lipolysis are the primary goals; stimulant-driven fat mobilization is the mechanism needed; localized subcutaneous fat at specific injection sites is the target; stacking Helios + carnitine for upstream lipolysis + downstream oxidation is the plan |
| GW501516 Dragon Pharma PPAR-Ξ΄ agonist Β· transcriptional fat oxidation upregulation |
GW501516 activates PPAR-delta, a nuclear receptor that transcriptionally upregulates the entire fat oxidation gene program β including CPT-1 expression, mitochondrial biogenesis, and beta-oxidation enzyme production; this is a longer-acting, gene-level upregulation of fat-burning capacity versus carnitine's acute substrate-level support; GW501516 increases fatty acid oxidation across all tissues, improves endurance capacity, and shifts whole-body metabolism toward fat as a primary fuel; carnitine acts at the protein/enzyme level on an immediate basis; both target the mitochondrial fat oxidation pathway but at different regulatory layers | Immediate pre-workout fat oxidation support at the substrate level; AAS stack complement; no oral administration (injectable only protocol); no desire for gene-level metabolic reprogramming | Sustained metabolic shift toward fat oxidation across the full day and training period is the goal; endurance performance enhancement via PPAR-delta is the primary objective; stacking GW501516 + injectable carnitine for complementary gene-level + substrate-level fat oxidation coverage is the plan |
Combinations
| Goal | Stack | Protocol / Timing | Notes |
|---|---|---|---|
| Fat oxidation maximization β lipolysis + transport | L-Carnitine 500 + Helios Dragon Pharma | Helios 0.5β1 ml SubQ into target fat area 30β45 min pre-workout; L-Carnitine 1,000β2,000 mg IM 20β30 min pre-workout. Sequence: Helios first to mobilize FFA; carnitine ensures the mobilized FFA are transported into mitochondria for oxidation rather than reesterified. Train within the 30β60 min post-Helios window while adrenergic lipolysis is active | Mechanistically complementary stack: Helios mobilizes FFA from adipocytes (upstream lipolysis); carnitine handles the downstream mitochondrial transport. The combination covers both bottlenecks in the fat-utilization cascade. Begin Helios at lowest effective dose (0.5 ml) and titrate based on cardiovascular tolerance. Monitor resting heart rate; if HR >100 bpm at rest, reduce Helios dose before adding carnitine. |
| AAS cycle complement β androgen receptor upregulation + lean preservation | L-Carnitine 500 + testosterone base (e.g. Enantat 250 Dragon Pharma) | L-Carnitine 1,000β2,000 mg IM 3β5Γ/week pre-workout throughout the AAS cycle; administer on training days to coincide with post-workout insulin spike and maximize muscle carnitine uptake. No timing constraint relative to AAS injection day | L-Carnitine's documented androgen receptor upregulation in skeletal muscle makes it a logical cycle addition: higher AR density may amplify the anabolic response to the same circulating testosterone. Carnitine also supports fat oxidation during a lean bulk, helping partition energy toward muscle rather than fat tissue. No interactions with AAS pharmacology β add at any point in the cycle. |
| GH axis stack + fat oxidation substrate support | L-Carnitine 500 + CJC-1295 DAC Dragon Pharma + Ipamorelin Dragon Pharma | CJC-1295 DAC 2 mg SubQ once weekly + Ipamorelin 200 mcg SubQ 2Γ/day fasted; L-Carnitine 1,000 mg IM on training days pre-workout. GH-driven lipolysis releases FFA into circulation; injectable carnitine ensures those mobilized FFA are transported into mitochondria for oxidation during the training session | GH stimulates lipolysis in adipose tissue (upstream FFA mobilization); carnitine addresses the downstream transport step. The combination ensures that both the lipolytic signal and the mitochondrial import capacity are optimized simultaneously. No pharmacological interactions between the compounds β distinct mechanisms at different points in the fat-burning pathway. |
Side Effects & Management
| Side Effect | Severity | How to Handle It |
|---|---|---|
| Injection site discomfort / burning | Low β common, brief | L-Carnitine solution at 500 mg/mL has a low pH and relatively high osmolality; IM injection of 2β4 mL volumes can produce a burning or stinging sensation during and immediately after injection. Inject slowly over 30β60 seconds β do not push rapidly. Use a 23β25 G needle for IM; warm the ampoule to body temperature before drawing. Rotate injection sites between deltoid, ventroglute, and vastus lateralis. Diluting the dose with 1β2 mL of normal saline in the syringe before injection reduces local irritation at higher dose volumes. |
| Nausea / GI discomfort | Low β dose-dependent at high doses | At doses of 2,000 mg or above, some users report mild nausea or stomach discomfort, particularly if injected rapidly or on an empty stomach. Inject slowly; allow 10β15 minutes between injection and the start of exercise. If nausea persists, reduce dose from 2,000 to 1,000 mg and re-titrate. The injectable route bypasses the GI carnitine-TMAO fermentation pathway (which causes the characteristic fishy odor and GI symptoms associated with oral carnitine at high doses), so GI symptoms from injectable L-carnitine are significantly less common than from oral supplementation. |
| Fishy body odor (TMAO) | Significantly reduced vs oral route | Oral L-carnitine undergoes gut microbial conversion to trimethylamine (TMA), which is then oxidized to trimethylamine N-oxide (TMAO) in the liver; TMAO is excreted through sweat and urine, producing a characteristic fishy odor. Injectable carnitine bypasses gut microbiome-mediated TMA production almost entirely. Residual TMA production from the small fraction metabolized hepatically is typically not perceptible. This is one of the practical advantages of the injectable format for users who previously experienced the odor side effect with oral supplementation. |
| Cardiovascular effects (at supraphysiological doses) | Low at standard doses | At therapeutic IM doses (500β2,000 mg), cardiovascular effects from L-carnitine are not clinically significant. At very high IV infusion doses used in clinical cardiology (3β6 g IV over 30 min), transient decreases in blood pressure and mild vasodilation have been reported. The IM doses used in athletic protocols are well below this range. Blood pressure should be monitored as a general practice; Ecosprin (Aspirin) 75 mg/day is appropriate for cardiovascular support on extended multi-compound protocols but is not specifically indicated for L-carnitine. |
Bloodwork Monitoring
| Lab | When to Test | Target & Action Threshold |
|---|---|---|
| Lipid panel (HDL, LDL, triglycerides) | Baseline β week 8β12 | L-Carnitine supplementation has been associated with modest improvements in lipid profiles in several clinical trials β particularly reductions in triglycerides and improvements in HDL/LDL ratio. Baseline lipid panel documents pre-protocol levels. If the primary context is a concurrent AAS cycle (which suppresses HDL), carnitine's lipid support effect is a secondary benefit. Target: HDL >40 mg/dL, triglycerides <150 mg/dL, LDL <130 mg/dL. RosuvastatinΒ for AAS-related lipid management; carnitine is not a primary lipid therapy. |
| Fasting blood glucose | Baseline; optional at week 8 if using high-dose protocols (β₯2,000 mg/day) | L-Carnitine's role in reducing intramitochondrial acyl-CoA accumulation is associated with modest improvements in insulin sensitivity in some clinical data. Fasting glucose baseline is useful context for evaluating this effect in the individual user. Target: <100 mg/dL. Not a primary monitoring lab for L-carnitine alone; becomes more relevant when combined with AAS (which can increase insulin resistance) or high-calorie bulking protocols. |
| Creatine kinase (CK) β optional | Baseline + week 4, if high training volume is the primary use case | L-Carnitine has been shown to reduce post-exercise CK elevation (a marker of muscle membrane damage) in controlled training studies. Tracking CK across a carnitine protocol provides objective feedback on whether recovery is improving. Normal post-training CK: variable by individual and modality; values >5,000 IU/L after unaccustomed exercise are common and not pathological. A sustained downward trend in post-exercise CK peak values over 4β8 weeks of carnitine supplementation is a positive efficacy signal. |
| Blood pressure | Self-monitor weekly on multi-compound protocols | L-Carnitine alone does not meaningfully affect blood pressure at athletic doses. Monitoring is important in the context of stacks including Helios (adrenergic) or AAS. Target: <130/85 mmHg. If sustained >140/90 mmHg on a multi-compound stack: Amlip (Amlodipine) 5 mg/day or Sartel (Telmisartan) 40 mg/day; add Ecosprin (Aspirin) 75 mg/day for extended protocols. |
Protocol & Administration
Injection route and technique: IM injection is the standard route for athletic use. Use a 23β25 G Γ 25β38 mm needle; draw the required volume and inject slowly over 30β60 seconds into the deltoid (doses up to 2 mL), ventroglute (doses up to 4 mL), or vastus lateralis (doses up to 4 mL). At doses of 1,000 mg (2 mL) or below, a single-site injection is standard. At 2,000 mg (4 mL), split the dose across two sites (2 mL per site) to reduce local irritation and improve absorption. Warm the ampoule to body temperature before drawing. Slow IV push (500 mg over 2β3 minutes) is an alternative for clinical settings; IV infusion is outside the scope of self-administered athletic protocols.
Timing: inject 20β30 minutes pre-workout on training days for maximal delivery during the session. For recovery-focused use, inject immediately post-workout when muscle blood flow is elevated and insulin sensitivity is highest β this window maximizes muscle carnitine uptake via insulin-facilitated transport. Pre-bed injection is used by some practitioners for overnight metabolic support but is less evidenced than pre- or post-workout timing. Consuming carbohydrates within 60 minutes post-injection on non-fasting protocols improves muscle carnitine retention via the insulin transport pathway.
| Protocol | Dose | Volume | Frequency | Primary Goal |
|---|---|---|---|---|
| Entry / metabolic support | 500β1,000 mg | 1β2 mL IM (single site) | 3Γ/week on training days | Baseline fat oxidation support; recovery; AAS stack complement |
| Standard / pre-workout fat oxidation | 1,000β1,500 mg | 2β3 mL IM (single site) | 4β5Γ/week on training days, pre-workout | Cutting phase fat oxidation; Helios complement; high-volume training recovery |
| Advanced / deficit + high volume | 2,000 mg | 4 mL IM split across 2 sites (2 mL each) | 5Γ/week pre-workout; consider daily on hard deficit phases | Maximum fat oxidation efficiency; CK reduction; AR upregulation within AAS cycle |
Practical Summary
- Injectable carnitine delivers pharmacokinetic precision that oral capsules cannot: oral L-carnitine at practical supplement doses fails to meaningfully raise muscle carnitine concentrations in clinical studies; injectable delivery at 500 mg/mL bypasses gut absorption variability entirely; if maximizing muscle carnitine content is the goal, the injectable Dragon Pharma format is the only format with predictable tissue delivery
- L-Carnitine facilitates fat oxidation but does not directly stimulate lipolysis: carnitine acts downstream β it transports mobilized fatty acids into mitochondria; it does not mobilize fat from adipocytes; to maximize the stack, pair injectable carnitine with a lipolytic agent (Helios) so the upstream FFA mobilization and downstream FFA transport steps are both optimized; running carnitine alone in a positive energy balance does not produce meaningful fat loss
- Inject slowly over 30β60 seconds and split doses above 2,000 mg across two sites: the 500 mg/mL concentration is sufficient for burning and stinging sensations if pushed rapidly; slow injection and site splitting reduces local irritation and improves comfort significantly; diluting with 1β2 mL normal saline in the syringe is an option for sensitive users
- Time injection pre-workout or immediately post-workout for maximum muscle uptake: insulin-facilitated carnitine transport into muscle is the primary loading mechanism; the post-workout window with carbohydrate consumption provides the highest insulin-stimulated carnitine uptake; pre-workout injection ensures circulating carnitine is available during the session when beta-oxidation demand is highest
- No hormonal effects, no PCT, no cycle breaks required: L-carnitine has no androgenic activity, no HPG axis interaction, and no steroidogenic properties; it can be run year-round, during AAS cycles, between cycles, or as a standalone; no washout period is needed; the only limit is practical β on/off use aligned with training blocks is appropriate but not pharmacologically mandatory
Injectable L-Carnitine 500 Dragon Pharma addresses one of the fundamental biochemical requirements for efficient fat oxidation: ensuring that the LCFA transport machinery inside the mitochondrial membrane is not the bottleneck when lipolysis is active and fatty acids are available. As a standalone, it is a clean, side-effect-minimal metabolic support compound; within a multi-compound stack alongside Helios for lipolysis, GW501516 for gene-level fat oxidation upregulation, or AAS for androgen receptor density amplification, it covers the mitochondrial substrate delivery layer that no other compound directly addresses. Available at Steroid Warehouse in the 500 mg/mL Dragon Pharma format, it brings pharmaceutical-grade injectable precision to a compound that oral supplementation has consistently failed to deliver effectively to muscle tissue.
References
| Source | Topic | Link |
|---|---|---|
| Journal of Physiology / PubMed | Wall et al. 2011 β human study demonstrating that chronic L-carnitine plus carbohydrate ingestion can raise skeletal muscle carnitine content; reports altered fuel metabolism during exercise, including reduced muscle glycogen use and changes consistent with greater fat oxidation during lower-intensity work | Wall BT, et al. (2011) β |
| American Journal of Clinical Nutrition / PubMed | Brass 2000 β review of supplemental carnitine and exercise; covers proposed mechanisms including fatty acid oxidation, glucose homeostasis, acylcarnitine formation, training-response modification, fatigue resistance, and the limitations of existing human performance evidence | Brass EP (2000) β |
| Annals of the New York Academy of Sciences / PubMed | Rebouche 2004 β detailed review of L-carnitine and acetyl-L-carnitine kinetics, pharmacokinetics, and metabolic regulation; covers dietary absorption, endogenous synthesis, tissue distribution, renal conservation, clearance, and systemic handling of exogenous carnitine | Rebouche CJ (2004) β |
| American Journal of Physiology-Endocrinology and Metabolism / PubMed | Volek et al. 2002 β controlled crossover study in resistance-trained men showing that L-carnitine L-tartrate supplementation favorably affects markers of recovery from exercise stress, including biochemical markers linked to purine catabolism, free radical formation, and muscle tissue disruption after squat exercise | Volek JS, et al. (2002) β |
| FASEB Journal / PubMed | Stephens et al. 2006 β human study showing that insulin can acutely increase skeletal muscle total carnitine content during hypercarnitinemia; supports the mechanism that insulin-dependent transport, not only systemic carnitine availability, is central to muscle carnitine loading | Stephens FB, et al. (2006) β |
How to take L-Carnitine 500 mg?
Inject 500-1000 mg daily or EOD; see How to Use. Use sterile techniqueβconsult for proper administration.
How to use L-Carnitine 500 mg?
Inject 1-2 ml daily or EOD, pre-workout or morning; see How to Use. Combine with diet and cardioβconsult professionals for tailored plans.
What is L-Carnitine 500?
L-Carnitine 500 is an injectable amino acid derivative for fat metabolism; see What is L-Carnitine. It enhances energyβconsult professionals for safe use.
How long does L-Carnitine 500 stay in your system?
With a 1-2 hour half-life, it's detectable for ~4-6 hours; see Mechanism of Action. Effects are short-livedβconsult professionals for cycles.
What is L-Carnitine 500 commonly used for?
L-Carnitine 500 is commonly associated with:
- Energy and endurance support
- Fat metabolism and body composition discussions
- Workout recovery and performance-focused routines
- Wellness and metabolic-support protocols
It is widely discussed in fitness and wellness communities.
Why is L-Carnitine popular in fitness and fat-loss protocols?
Users often choose L-Carnitine because it may:
- Support energy utilization during exercise
- Complement fat-loss and conditioning goals
- Promote workout recovery and endurance support
It is commonly discussed in cutting and athletic-performance routines.
Is L-Carnitine 500 mg used for fat loss?
L-Carnitine is often included in fat-loss and body recomposition programs, but its effects are most noticeable when combined with proper diet and exercise.
What are the possible side effects of L-Carnitine 500 mg?
Possible side effects may include mild gastrointestinal discomfort, nausea, or a fishy body odor in some individuals at higher intake levels.
Related Products
